Tumor volume and metabolism of prostate cancer determined by proton magnetic resonance spectroscopic imaging at 3T without endorectal coil reveal potential clinical implications in the context of radiation oncology.

PURPOSE To determine whether a relationship exists between the tumor volume (TV) or relative choline content determined using magnetic resonance spectroscopy imaging (MRSI) at 3T and the clinical prognostic parameters for patients with localized prostate cancer (PCa). METHODS AND MATERIALS A total of 72 men (mean age, 67.8 ± 6.2 years) were stratified as having low-risk (n = 26), intermediate-risk (n = 24), or high-risk (n = 22) PCa. MRSI was performed at 3T using a phased-array coil. Spectra are expressed as the total choline/citrate, total choline plus creatine/citrate, and total choline plus polyamines plus creatine/citrate ratios. The mean ratio of the most pathologic voxels and the MRSI-based TV were also determined. RESULTS The mean values of the total choline/citrate, total choline plus creatine/citrate, and total choline plus polyamine plus creatine/citrate ratios were greater for Stage T2b or greater tumors vs. Stage T2a or less tumors: 7.53 ± 13.60 vs. 2.31 ± 5.65 (p = .018), 8.98 ± 14.58 vs. 2.56 ± 5.70 (p = .016), and 10.32 ± 15.47 vs. 3.55 ± 6.16 (p = .014), respectively. The mean MRSI-based TV for Stage T2b or greater and Stage T2a or less tumors was significantly different (2.23 ± 2.62 cm(3) vs. 1.26 ± 2.06 cm(3), respectively; p = .030). This TV correlated with increased prostate-specific antigen levels (odds ratio, 1.293; p = .012). Patients with high-risk PCa had a larger TV than did the patients with intermediate-risk PCa. A similar result was found for the intermediate-risk group compared with the low-risk group (odds ratio, 1.225; p = .041). CONCLUSION Biomarkers expressing the relative choline content and TV were significant parameters for the localization of PCa and could be helpful for determining the prognosis more accurately.

[1]  Jacob Sosna,et al.  MR imaging of the prostate at 3 Tesla: comparison of an external phased-array coil to imaging with an endorectal coil at 1.5 Tesla. , 2004, Academic radiology.

[2]  P. Carroll,et al.  Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. , 1996, Radiology.

[3]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[4]  M. Kattan,et al.  Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. , 2005, Radiology.

[5]  J. McNeal.  Cancer volume and site of origin of adenocarcinoma in the prostate: relationship to local and distant spread. , 1992, Human pathology.

[6]  Katarzyna J Macura,et al.  Prostate cancer: sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy--results of ACRIN prospective multi-institutional clinicopathologic study. , 2009, Radiology.

[7]  H. Huisman,et al.  Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. , 2006, Radiology.

[8]  T. Scheenen,et al.  Three-dimensional proton MR spectroscopy of human prostate at 3 T without endorectal coil: feasibility. , 2007, Radiology.

[9]  P. Walsh,et al.  Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. , 2002, The Journal of urology.

[10]  A. D'Amico,et al.  Calculated prostate carcinoma volume , 1998, Cancer.

[11]  D. Kuban,et al.  Biochemical and clinical significance of the posttreatment prostate‐specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone , 2006, Cancer.

[12]  R E Lenkinski,et al.  Prostate: MR imaging with an endorectal surface coil. , 1989, Radiology.

[13]  J Kurhanewicz,et al.  Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. , 2000, The Journal of urology.

[14]  G. Mantell.  REMARKS ON PARTIAL FRACTURE OF THE RADIUS. , 1841 .

[15]  J. Kurhanewicz,et al.  Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT. , 2007, Radiology.

[16]  M. Kattan,et al.  Comparison of endorectal magnetic resonance imaging, guided prostate biopsy and digital rectal examination in the preoperative anatomical localization of prostate cancer. , 2005, The Journal of urology.

[17]  P. Carroll,et al.  Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging--clinicopathologic study. , 1999, Radiology.

[18]  J. Cosset,et al.  [PSA bounce after permanent implant prostate brachytherapy may mimic a biochemical failure]. , 2007, Cancer Radiothérapie.

[19]  D. Bostwick,et al.  Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density. , 1994, The Journal of urology.

[20]  Nobuhiko Hata,et al.  Quantitative MR imaging assessment of prostate gland deformation before and during MR imaging-guided brachytherapy. , 2002, Academic radiology.

[21]  H. Hricak,et al.  Regarding the focal treatment of prostate cancer: inference of the Gleason grade from magnetic resonance spectroscopic imaging. , 2009, International journal of radiation oncology, biology, physics.

[22]  S. Mancino,et al.  Combined morphological, [1H]-MR spectroscopic and contrast-enhanced imaging of human prostate cancer with a 3-Tesla scanner: preliminary experience , 2008, La radiologia medica.

[23]  P. Carroll,et al.  Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system. , 2004, Radiology.

[24]  P. Carroll,et al.  Spectroscopy in prostate cancer: hope or hype? , 2001, Oncology.

[25]  H. Huisman,et al.  Prostate cancer: precision of integrating functional MR imaging with radiation therapy treatment by using fiducial gold markers. , 2005, Radiology.

[26]  T. Stamey,et al.  PATTERNS OF PROGRESSION IN PROSTATE CANCER , 1986, The Lancet.

[27]  Jelle O. Barentsz,et al.  Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis , 2002, European Radiology.

[28]  Henrik Grönberg,et al.  Prostate cancer epidemiology , 2003, The Lancet.

[29]  L. Tanoue.  Cancer Statistics, 2009 , 2010 .

[30]  H. Ahlström,et al.  Two-dimensional spectroscopic imaging for pretreatment evaluation of prostate cancer: comparison with the step-section histology after radical prostatectomy. , 2009, Magnetic resonance imaging.

[31]  J. Cosset,et al.  PSA bounce after permanent implant prostate brachytherapy may mimic a biochemical failure: a study of 295 patients with a minimum 3-year followup. , 2006, Brachytherapy.

[32]  C. Bangma,et al.  Overdiagnosis and overtreatment of early detected prostate cancer , 2007, World Journal of Urology.

[33]  Mauricio Castillo,et al.  Clinical role of proton magnetic resonance spectroscopy in oncology: brain, breast, and prostate cancer. , 2006, The Lancet. Oncology.

[34]  I. Hsu,et al.  Pretreatment endorectal magnetic resonance imaging and magnetic resonance spectroscopic imaging features of prostate cancer as predictors of response to external beam radiotherapy. , 2009, International journal of radiation oncology, biology, physics.

[35]  H M Pollack,et al.  Magnetic resonance imaging of the prostate gland , 1990, Urologic radiology.

[36]  J. Kurhanewicz,et al.  Very selective suppression pulses for clinical MRSI studies of brain and prostate cancer , 2000, Magnetic resonance in medicine.

[37]  J. Pauly,et al.  Dualband spectral‐spatial RF pulses for prostate MR spectroscopic imaging , 2001, Magnetic resonance in medicine.

[38]  L. Collette,et al.  Impact of pathology review of stage and margin status of radical prostatectomy specimens (EORTC trial 22911) , 2006, Virchows Archiv.

[39]  G. De Meerleer,et al.  A qualitative approach to combined magnetic resonance imaging and spectroscopy in the diagnosis of prostate cancer. , 2010, European journal of radiology.

[40]  A. Renshaw,et al.  Calculated prostate cancer volume: the optimal predictor of actual cancer volume and pathologic stage. , 1997, Urology.

[41]  Marco Zaider,et al.  Towards integrating functional imaging in the treatment of prostate cancer with radiation: the registration of the MR spectroscopy imaging to ultrasound/CT images and its implementation in treatment planning. , 2002, International journal of radiation oncology, biology, physics.

[42]  M. Kattan,et al.  The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis , 2007, BJU international.

[43]  Sharyn I. Katz,et al.  MR imaging and MR spectroscopy in prostate cancer management. , 2006, Radiologic clinics of North America.

[44]  J. Kirkpatrick.  Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. , 1998, Journal of insurance medicine.

[45]  J Kurhanewicz,et al.  Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. , 1999, Radiology.

[46]  Adam S. Kibel,et al.  Screening and Prostate-Cancer Mortality in a Randomized European Study , 2009 .

[47]  L. Kiemeney,et al.  Changes in prostate shape and volume and their implications for radiotherapy after introduction of endorectal balloon as determined by MRI at 3T. , 2009, International journal of radiation oncology, biology, physics.

[48]  Amita Shukla-Dave,et al.  The role of MRI and MRSI in diagnosis, treatment selection, and post-treatment follow-up for prostate cancer. , 2009, Clinical advances in hematology & oncology : H&O.